Truist analyst Tobey Sommer lowered the firm’s price target on Insperity (NSP) to $70 from $82 and keeps a Hold rating on the shares after its Q1 earnings miss and below-consensus guide. The firm is citing deteriorating SMB sentiment and risks of further healthcare issues, along with higher healthcare utilization, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSP: